Advancing Innovative
Oral Medicines
for people with inflammatory and
autoimmune diseases

Selectively modulating
key immune targets

To create differentiated medicines

Ventyx is a clinical-stage biopharmaceutical company focused on developing innovative oral medicines for patients living with autoimmune and inflammatory disorders. We believe our ability to efficiently discover and develop differentiated drug candidates will allow us to address important unmet medical needs with novel oral therapies that shift the immunology markets from injectables to oral drugs. Our current pipeline includes four clinical-stage programs targeting NLRP3, S1P1R and TYK2.


Our approach allows us to streamline the discovery and development process.


Learn about our differentiated clinical-stage candidates and preclinical programs.


We are passionate about advancing novel therapies to improve the lives of patients.

Featured News